LINEVERO

This brand name is authorized in Poland

Active ingredients

The drug LINEVERO contains one active pharmaceutical ingredient (API):

1 Everolimus UNII 9HW64Q8G6G - EVEROLIMUS
Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. Read about Everolimus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EG02	Everolimus	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L01EG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100386143, 100386172, 100386195

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.